SJ733 treatment in Malaria
SJ733 treatment as a Possible Radical Cure for Malaria
SEE ALL PARTNER ORGANIZATIONS
Objectives
- Combination of SJ733 with Tafenoquine as a Possible Radical Cure for P. vivax Malaria
- Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria
SJ733 is expected to be suitable for treatment in malaria-endemic areas, with rapid efficacy and safety, and providing lasting protection against reinfection. The treatment might potentially solve the problem of increased resistance faced by current antimalarial medicines. In the ongoing collaboration with the University of Kentucky, Eisai is responsible for the provision of drug substance and formulation manufacturing. The Phase II clinical study is being conducted in Peru by the University of Kentucky.
Results and milestones
SJ733 is a novel antimalarial drug currently being developed for the treatment of uncomplicated malaria. SJ733 has demonstrated pharmacodynamics, tolerability, safety, and efficacy in human clinical trials. We will assess the safety, tolerability, efficacy, and pharmacokinetics of an orally administered fixed-dose combination of SJ733 and TQ with the aim of showing the combination would radically cure P. vivax malaria with a substantial improvement in schedule and better efficacy than current radical cure drugs.
Geographic Reach
- Global Commitment
Disease Area
- Infectious and Parasitic Disease
Target Population
- Men
- Women
- People with low incomes
Partner organizations
University of Kentucky
Geographic Reach
Global Commitment
Disease Area
Infectious and Parasitic Disease
- Malaria